GLOBUS MEDICAL INC
For the period ended Dec 31, 2024. Filed Feb 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 20, 2025
GMED$75.23-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income
| Year Ended | |||
|---|---|---|---|
| December 31, | |||
| (In thousands, except per share amounts) | 2024 | 2023 | 2022 |
| Net sales | $2,519,355 | $1,568,476 | $1,022,843 |
| Cost of Sales and Operating expenses: | |||
| Cost of sales (exclusive of amortization of intangibles) | 1,035,479 | 548,174 | 263,725 |
| Research and development | 163,754 | 124,010 | 73,015 |
| Selling, general and administrative | 981,048 | 643,410 | 432,117 |
| Provision for litigation, net | 314 | 434 | 2,341 |
| Amortization of intangibles | 119,373 | 51,032 | 17,735 |
| Acquisition-related costs | 29,623 | 68,274 | 5,959 |
| Restructuring costs | 23,773 | — | — |
| Operating income/(loss) | 165,991 | 133,142 | 227,951 |
| Other income/(expense), net | |||
| Interest income/(expense), net | (4,189) | 20,130 | 14,233 |
| Foreign currency transaction gain/(loss) | (43,285) | 14,259 | (1,020) |
| Other income/(expense) | 2,205 | (2,138) | 1,855 |
| Total other income/(expense), net | (45,269) | 32,251 | 15,068 |
| Income/(loss) before income taxes | 120,722 | 165,393 | 243,019 |
| Income tax provision/(benefit) | 17,738 | 42,520 | 52,850 |
| Net income/(loss) | $102,984 | $122,873 | $190,169 |
| Other comprehensive income/(loss), net of tax: | |||
| Unrealized gain/(loss) on marketable securities | 1,545 | 13,231 | (14,040) |
| Foreign currency translation gain/(loss) | 1,786 | 1,207 | (3,818) |
| Total other comprehensive income/(loss), net of tax | 3,331 | 14,438 | (17,858) |
| Comprehensive income/(loss) | $106,315 | $137,311 | $172,311 |
| Earnings per share: | |||
| Basic | $0.76 | $1.09 | $1.89 |
| Diluted | $0.75 | $1.07 | $1.85 |
| Weighted average shares outstanding: | |||
| Basic | 135,726 | 113,087 | 100,469 |
| Diluted | 137,863 | 114,630 | 102,643 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.